Comments
Buoyed by growth in the US, drugmaker Lupin has got off to a robust start this financial year, clocking a 55 per cent growth in net profit for the first quarter ended June 30.
Business is at an all-time high with record revenues and profits driven by strong growth in the US and India, Nilesh Gupta, Managing Director, said in a statement. Lupin’s US revenues increased 46 per cent to $262 million during the three months under review.
The US market accounts for almost half of Lupin’s net sales.
Sales of its finished medicines business saw a 57 per cent spike to clock ₹1,605 crore in the quarter. Its India business grew 29 per cent recording net revenues of ₹761 crore in the quarter under review. Japan, the third growth market for Lupin grew 17 per cent to register net sales of ₹341 crore in the quarter under review.
The Japan business includes sales from its subsidiaries Kyowa and I’rom.
Lupin’s API (active pharmaceuticals ingredients) business grew 20 per cent to ₹292 crore in the quarter. The company’s research spends for the quarter increased over 7 per cent of net sales to ₹243 crore.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.